色偷偷wwww88888,少妇熟女高潮流白浆,极品人妻VIDEOSSS人妻,九九热在线视频观看这里只有精品

加拿大Angiotech  
AngioTech是加拿大的上市公司，主要業(yè)務(wù)為制藥和醫(yī)療器械，總部在溫哥華，是由幾個著名外科醫(yī)生創(chuàng)辦的，也是醫(yī)生把技術(shù)和專利轉(zhuǎn)化成產(chǎn)品的成功例子。該公司成立以來，業(yè)務(wù)增長非常迅速，目前分別在歐洲的丹麥、美國的芝加哥和加州設(shè)有分支機(jī)構(gòu)，該公司發(fā)明的“血管支架”、“手術(shù)縫合針線”等醫(yī)療產(chǎn)品技術(shù)非常先進(jìn)，可以說改變了外科手術(shù)的潮流，一旦這些新產(chǎn)品上市，該公司的業(yè)務(wù)將以幾何倍數(shù)增長。
Angiotech是比較年輕的特種藥物和醫(yī)療設(shè)備公司，為醫(yī)療器件植入、外科手術(shù)干預(yù)和急性損傷相關(guān)疾病或并發(fā)癥提供創(chuàng)新的治療解決方案。

這間加拿大公司成立于1992年，作為共同創(chuàng)始人之一的William Hunter博士（現(xiàn)為CEO）當(dāng)時還是卑斯大學(xué)的醫(yī)科學(xué)生。Angiotech同各所大學(xué)和業(yè)界結(jié)成戰(zhàn)略聯(lián)盟，為其產(chǎn)品的商品化開辟渠道。加拿大政府的國家研究委員會有工業(yè)研究協(xié)助計劃（NRC-IRAP），對于幫助該公司將科學(xué)理念轉(zhuǎn)化為可應(yīng)用的治療解決方案也起到重要作用。

最初的開拓性開發(fā)項目之一是將紫杉醇這種藥物輸送到疾病部位以抑制血管生成的技術(shù)；血管生成會促進(jìn)腫瘤、關(guān)節(jié)炎和其它慢性病的發(fā)展。紫杉醇經(jīng)過加工用在TAXUS?冠狀動脈支架中，由Boston Scientific Corporation營銷和分銷，已植入世界各地400多萬病人的體內(nèi)。

“加拿大政府通過NRC-IRAP等計劃支持私營企業(yè)的研究工作，支持我們的創(chuàng)新文化，起到極其重要的作用，”Hunter博士說。

Angiotech [www.angiotech.com] 是加拿大在生命科學(xué)界占領(lǐng)先地位的又一個極好的范例。

補(bǔ)充資料

Angiotech在世界各地有1,300多名盡忠職守的員工。在加拿大，該企業(yè)的溫哥華總辦事處有近100名員工。
Angiotech目前有250多項美國專利和230多項美國專利待批申請。該公司的技術(shù)范圍廣泛，包括控制出血的止血鉗和便于接通動脈的人工血管。
Angiotech是上市公司，其股票在多倫多證券交易所和納斯達(dá)克買賣。

Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury. We are listed on both the TSX and NASDAQ stock exchanges (TSX: ANP, NASDAQ: ANPI). The company's initial lead product, the TAXUS? drug-eluting coronary stent - which was co-developed and is now sold by Boston Scientific Corporation - is implanted in over four million patients worldwide.

We develop our products using a proprietary and systematic discovery approach. We use our drug screening capabilities to identify new uses for known pharmaceutical compounds. We look for compounds that address the underlying biological causes of conditions that can occur concurrently with medical device implantation, surgery or acute trauma. Once appropriate drugs have been identified, we formulate the drug, or combination of drugs, with our portfolio of biomaterials and drug delivery technologies to develop a novel drug-eluting medical device or surgical implant.

We have patent protected our technology and many of our products and potential product candidates, and our portfolio of intellectual property developed, licensed or acquired includes over 250 issued U.S. patents and 230 pending U.S. patent applications as of December 2007.

Following the acquisition of American Medical Instruments Holdings, Inc. in 2006, Angiotech expanded beyond its strong R&D capabilities to encompass the manufacturing and marketing of a wide range of single use, specialty medical devices, focused on interventional, surgical and OEM markets. Angiotech is currently working to develop a portfolio of next-generation products including its innovative Quill? SRS, which is a bidirectional, barbed wound-closure device. Today, Angiotech has several specialized direct sales and distribution organizations in the United States and the European Union, as well as significant manufacturing capabilities.

At Angiotech, we are redefining success by striving to create novel medical solutions that elevate the standard of care and improve people's lives.